Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
about
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectivesBreast cancer intrinsic subtype classification, clinical use and future trendsIdentifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomesGenomic profiling in luminal breast cancerMolecular Technologies in the Clinical Diagnostic LaboratoryCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyQuantification of HER family receptors in breast cancerHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenStatistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practiceUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensLimitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.A prognostic model of triple-negative breast cancer based on miR-27b-3p and node statusSelecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment.PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).Functional characterization of breast cancer using pathway profilesMolecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerPredictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Genome-based risk prediction for early stage breast cancer.Age-specific changes in intrinsic breast cancer subtypes: a focus on older womenEmerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Multigene prognostic tests in breast cancer: past, present, futureMarkers for the identification of late breast cancer recurrence.p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.Estrogen receptor expression is high but is of lower intensity in tubular carcinoma than in well-differentiated invasive ductal carcinoma.Intra-tumour signalling entropy determines clinical outcome in breast and lung cancer.The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatmentHighlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.Relapse profile of early breast cancer according to immunohistochemical subtypes: guidance for patient's follow up?Molecular characterization and targeted therapeutic approaches in breast cancer
P2860
Q26768119-F88FC235-68A9-48A3-810B-D6C1399102A6Q26773761-D9F771B3-91C2-4D79-9C07-4C547910F034Q26778675-2B2FA7E4-BBA3-47CD-B8C2-1526162E4712Q26862681-1367C22E-6FF5-4F39-A828-92F32CE3096FQ26996463-3C70505F-6A09-4EFA-94A5-74F1AA321266Q27011658-C0B49127-7D38-4526-9B41-179ED6C6EB9DQ27015506-70AAADCF-6537-488F-A0CA-22627ECB4193Q28077637-2B54578A-2C0A-4537-AD34-DD05647E01CBQ28078729-3C4C55C8-6756-4005-B40B-AC390C126204Q28079118-35C9BBAD-2025-405F-9EAF-820F9FD5D210Q28085062-5ACB819E-17A9-46D5-81ED-03C268D02EC9Q30315367-2BD71908-6E9E-4A89-84FD-75ECADF04366Q30978083-87E4ADD6-B66E-45A6-8D93-DC73111A5931Q33559365-D5CBA4EB-A6F6-4B06-9028-86B5CE999F9CQ33591751-F4C89B2B-EF43-4EC5-957D-CF6658405795Q33660598-671FD9DB-532B-4682-B224-780DD11DDD39Q33684843-CCAF79BC-CE1E-41BD-A348-7405C64EE043Q33756398-AE75BB64-A531-405D-84BB-C5503B127143Q33779774-52E28A53-2273-4A76-A67B-A8DCEEAE47B4Q33834198-216FCA1F-A7A8-487B-A6BC-EF554AD071FBQ33843799-35FC22CD-4010-49D5-B9EA-44213A2D8C23Q33859760-A52B77FD-9C8F-45F6-BFD4-578D24AFF1ECQ33883406-B0C24643-E977-4C9C-87A4-F2A84CF974F1Q33962784-64373321-AFF4-4A4D-B14B-F8CC38256B1FQ34120668-126F032A-88CD-4AD6-8220-158C45F24DEBQ34171119-C3AAA49A-A275-4B9C-A09D-4FAF886C4838Q34359289-79F62A9B-7BC6-436A-8B72-9F5440214A9EQ34359310-61C84BDA-D852-477D-AC2B-BD64D3D23327Q34657656-9B88F9DA-A2AE-4F1A-A4E1-D826079A8162Q34694845-605F49F0-7C18-48B1-9847-4CE31A5B7A18Q34736075-3604D5F0-D39F-4291-8FA5-E71451F36166Q35018599-34311247-4707-449F-9199-BCD7712F510EQ35018949-C5A478B8-5AE3-47C3-B00C-7A141A739426Q35051755-2627A41D-5F0D-43E2-9627-B064CCF04E40Q35083016-034030EB-7A6D-475D-A1C2-672F021BF260Q35203271-08959907-C3F8-422C-B200-A6C02945915BQ35345599-5BBD85F6-16DF-44B0-B205-68EF3380A37FQ35496344-D516D317-C302-48B9-9AAF-894548D4ED6CQ35528917-FB0F6758-09F6-474F-B71A-5D77B3A409BBQ35530143-DC28257F-62EF-46D4-8772-967E342CE2BE
P2860
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@ast
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@en
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@nl
type
label
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@ast
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@en
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@nl
prefLabel
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@ast
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@en
Comparison of PAM50 risk of re ...... rence after endocrine therapy.
@nl
P2093
P50
P356
P1476
Comparison of PAM50 risk of re ...... rrence after endocrine therapy
@en
P2093
Carl Schaper
J Wayne Cowens
Jack Cuzick
James Storhoff
Kalvinder Sidhu
Mitch Dowsett
Sean Ferree
P304
P356
10.1200/JCO.2012.46.1558
P407
P577
2013-07-01T00:00:00Z